Matinas BioPharma Holdings, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Matinas BioPharma amended its Certificate of Incorporation to effect a 15-for-1 reverse split of its common stock, effective September 28, 2026. The authorized share count remains 510M total (500M common, 10M preferred). Fractional shares will be paid in cash at the closing price on the last trading day before effectiveness. The action was approved by the board and stockholders.
Why this rating
Reverse split is a routine capital structure adjustment common in micro-cap distressed companies; does not alter business fundamentals, revenue, or cash position relative to $4.5M market cap.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.